Advocate on issues related to regulation of, access to, and reimbursement for regenerative medicine companies and products; FDA appropriations and staffing, specifically at CBER and OT; FDA oversight, including adaptive regulatory pathways for cell and gene therapies; Value-based payment legislation and related CMS regulations; Biologics regulation; Prescription Drug User Fee Act (PDUFA); Medicaid; Medicare; NIH appropriations; HHS oversight; HHS staffing and OPM issues; Federal support of medical research; Pharmaceutical tariffs; Biotechnology manufacturing.
2026 · 2nd Quarter (Apr 1 - June 30)
ALLIANCE FOR REGENERATIVE MEDICINE
Filed by ALLIANCE FOR REGENERATIVE MEDICINE.
Open official filingSource-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 17, 2026
- Income
- Not reported
- Expenses
- $120,000.00
- Registrant
- ALLIANCE FOR REGENERATIVE MEDICINE
- Filing UUID
- 1134cadf-51ae-4dc9-94d0-3551da9441ac
- Termination date
- Not reported
Expense method: C
Literal source text
Lobbying issues and bill citations
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.